Therapy
125 tracked therapy entities, ordered by how much was published about each in the last 30 days. 363 papers across 103 of them.
- Inhibitor 15 papers
- Cisplatin 13 papers
- Immunotherapy 13 papers
- Intervention 13 papers
- Radiation therapy 10 papers
- Checkpoint inhibitor 9 papers
- Combination therapy 9 papers
- Bevacizumab 8 papers
- Glucagon-like peptide-1 receptor agonist 8 papers
- Monoclonal antibody 8 papers
- Dexamethasone 7 papers
- CAR-T cells 6 papers
- Doxorubicin 6 papers
- Gemcitabine 6 papers
- Nivolumab 6 papers
- Paclitaxel 6 papers
- Platinum 6 papers
- Rituximab 6 papers
- Semaglutide 6 papers
- Anti-PD-1 therapy 5 papers
- Atezolizumab 5 papers
- Atorvastatin 5 papers
- Capecitabine 5 papers
- Chemoradiotherapy 5 papers
- Influenza vaccine 5 papers
- Methotrexate 5 papers
- Pembrolizumab 5 papers
- Anti-PD-L1 4 papers
- Ciprofloxacin 4 papers
- Durvalumab 4 papers
- Fluorouracil 4 papers
- Gene therapy 4 papers
- Sodium glucose cotransporter-2 (SGLT2) inhibitors 4 papers
- Sorafenib 4 papers
- Trastuzumab 4 papers
- Upadacitinib 4 papers
- Antimicrobial 3 papers
- Aspirin 3 papers
- Carboplatin 3 papers
- Cyclophosphamide 3 papers
- Dupilumab 3 papers
- HPV vaccine 3 papers
- Infliximab 3 papers
- Interferon gamma 3 papers
- Lenalidomide 3 papers
- Lenvatinib 3 papers
- Levodopa 3 papers
- Photobiomodulation 3 papers
- Rivaroxaban 3 papers
- RNA vaccine 3 papers
- Simvastatin 3 papers
- Statin 3 papers
- Temozolomide 3 papers
- Vitamin D 3 papers
- Aflibercept 2 papers
- Alectinib 2 papers
- Amphotericin B 2 papers
- Antibody-drug conjugate 2 papers
- Celecoxib 2 papers
- Chemoimmunotherapy 2 papers
- COVID-19 vaccine 2 papers
- Enfortumab vedotin 2 papers
- Fenofibrate 2 papers
- Finerenone 2 papers
- Histone deacetylase inhibitors 2 papers
- Ibuprofen 2 papers
- Ipilimumab 2 papers
- Janus kinase inhibitors 2 papers
- Liraglutide 2 papers
- Melatonin 2 papers
- Meropenem 2 papers
- Metformin 2 papers
- Olaparib 2 papers
- Oxaliplatin 2 papers
- Rutin 2 papers
- Tirzepatide 2 papers
- Tislelizumab 2 papers
- Abemaciclib 1 paper
- Adalimumab 1 paper
- Bacillus Calmette-Guérin 1 paper
- Belimumab 1 paper
- Bortezomib 1 paper
- Cabozantinib 1 paper
- Cetuximab 1 paper
- Cyclin-dependent kinase 4/6 inhibitors 1 paper
- Dasatinib 1 paper
- Dexmedetomidine 1 paper
- Docetaxel 1 paper
- Doxycycline 1 paper
- Empagliflozin 1 paper
- Gefitinib 1 paper
- Glucagon-like peptide-1 agonist 1 paper
- Glucocorticoid 1 paper
- Osimertinib 1 paper
- Palbociclib 1 paper
- PARP inhibitor 1 paper
- Photothermal therapy 1 paper
- Platelet-rich plasma 1 paper
- Sirolimus 1 paper
- Taxane 1 paper
- Tofacitinib 1 paper
- Trametinib 1 paper
- Venetoclax 1 paper
- [177Lu]Lu-PSMA-617
- Azithromycin
- Caelyx
- Calcineurin inhibitor
- Carbamazepine
- Ceftazidime-avibactam
- Cisplatin/fluorouracil
- Dapagliflozin
- Electroacupuncture
- Erlotinib
- Ibrutinib
- Immunization
- Insulin Therapy
- Intravitreal rituximab
- Niraparib
- Nirmatrelvir/ritonavir
- Nirsevimab
- PD-1/PD-L1 blockade
- Quercetin hydrogel
- Ruxolitinib
- Tyrosine-kinase inhibitor
- Vancomycin